KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in IntangiblesChange in InventoryDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNTech SE (BNTX) Capital Expenditures (2018 - 2025)

Historic Capital Expenditures for BioNTech SE (BNTX) over the last 8 years, with Q3 2025 value amounting to -$42.0 million.

  • BioNTech SE's Capital Expenditures rose 4750.61% to -$42.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$195.3 million, marking a year-over-year increase of 4066.74%. This contributed to the annual value of -$306.2 million for FY2024, which is 1409.15% down from last year.
  • According to the latest figures from Q3 2025, BioNTech SE's Capital Expenditures is -$42.0 million, which was up 4750.61% from -$30.7 million recorded in Q2 2025.
  • In the past 5 years, BioNTech SE's Capital Expenditures registered a high of -$26.18 during Q1 2021, and its lowest value of -$139.4 million during Q4 2022.
  • Its 5-year average for Capital Expenditures is -$64.6 million, with a median of -$63.6 million in 2024.
  • As far as peak fluctuations go, BioNTech SE's Capital Expenditures soared by 9999.96% in 2021, and later plummeted by 18909056451.41% in 2022.
  • BioNTech SE's Capital Expenditures (Quarter) stood at -$45.1 million in 2021, then plummeted by 209.2% to -$139.4 million in 2022, then skyrocketed by 35.3% to -$90.2 million in 2023, then increased by 21.07% to -$71.2 million in 2024, then soared by 41.03% to -$42.0 million in 2025.
  • Its last three reported values are -$42.0 million in Q3 2025, -$30.7 million for Q2 2025, and -$51.4 million during Q1 2025.